Search ABOUT PROGRAMS PLATFORM NEWS PUBLICATIONS INVESTORS CAREERS CONTACT BELIEVE ACHIEVE BENEFITS We believe that you, as an employee, matter above everything else. We back that statement up continuously with a unique approach to providing you with great benefits and valuable resources. Our benefits packages and resources are designed to support you in creating the life and work style that brings your best to your community, your family and Regulus’ mission of addressing significant unmet medical needs. Most of our benefits cover employees who work at least 30 hours a week and their eligible dependents. Eligible dependents include: A spouse or domestic partner Children (biological, step, foster, adopted or legal charge) up to age 26 The majority of our benefits become effective immediately on the date of hire without any pre-existing condition exclusion (temporary employees, contractors, interns and co-ops are not eligible for benefits). In addition to an array of health and financial benefits and learning opportunities, we offer competitive compensation and bonus programs that reward you for your contributions toward achieving the company’s mission and strategic goals. We also provide you with a wide range of services designed to help make life easier while you are at work, so you can spend your free time doing more of the things you enjoy most. © 2021 Regulus Therapeutics Inc. - All Rights Reserved Home | Legal | Contact

Search ABOUT PROGRAMS PLATFORM NEWS PUBLICATIONS INVESTORS CAREERS CONTACT BELIEVE ACHIEVE ADPKD About Autosomal Dominant Polycystic Kidney Disease (ADPKD) ADPKD, caused by the mutations in the PKD1 or PKD2 genes, is among the most common human monogenic disorders and a leading cause of end-stage renal disease. The disease is characterized by the development of multiple fluid filled cysts primarily in the kidneys, and to a lesser extent in the liver and other organs. Excessive kidney cyst cell proliferation, a central pathological feature, ultimately leads to end-stage renal disease in approximately 50% of ADPKD patients by age 60. About RGLS8429 RGLS8429 is a novel, second generation oligonucleotide designed to inhibit miR-17 and to preferentially target the kidney. RGLS8429 is supported both by robust data in preclinical models, where we have seen clear improvements in kidney function, size, and other measures of disease severity, as well as a superior pharmacologic profile. We have nominated RGLS8429 as a development candidate for the treatment of ADPKD. © 2021 Regulus Therapeutics Inc. - All Rights Reserved Home | Legal | Contact